ISSN 2167-0404
International Journal of Medicine and Medical Sciences ISSN 2167-0404 Vol. 5 (8), pp. 284-287, September, 2015. © International Scholars Journals
Full Length Research Paper
Efficacy and tolerance of combination of Cytidine 5 ' monophosphate (CMP) and Uridine-5 ' Triphosphate Trisodium (UTP) in patients with diabetic neuropathy: results of a study conducted in Dakar-Senegal
Lala Bouna Seck1, Anna Basse1, El Hachim Cissé2, Demba Diedhiou3, Kamadore Touré1,4, Moustapha Ndiaye1, Said Nourou Diop4, Mouhamadou Mansour Ndiaye1
1Department of Neurology, Fann University Teaching Hospital, Dakar-Senegal.
2Department of Neurosurgery, Fann University teaching hospital, Dakar-Senegal.
3Department of Internal Medicine and Antidiabetes Center, Abass Ndao National Hospital, Dakar-Senegal.
4Department of Health Sciences, University of Thies, Senegal.
Corresponding author. Email: [email protected]
Accepted April 20, 2015
Abstract
Diabetic neuropathy is the earliest and most common chronic complication of diabetes. There are numerous therapeutic methods, but most of them present a problem of efficacy and tolerance. NUCLEO CMP FORTE ® is a combination of nucleotides (Cytidine 5'- Monophosphate Disodium and Uridine -5' Triphosphate Trisodium). Several preclinical studies have demonstrated the effect the combination of CMP and UTP in the regeneration of the myelin sheath and nerve cells. The aim of this study was to evaluate the efficacy and safety of the combination of CMP and UTP in the treatment of diabetic neuropathy. In a prospective study, we conducted a 3-month clinical trial of the combination of CMP and UTP in 75 patients with diabetic neuropathy. The methods of investigation were clinical (Visual Analogous Scale, Neuropathy Disability Scale and Neuropathy Symptom Scale), electrophysiological (electromyography) and biochemical (liver and kidney function tests). The patients (68) had a mean age of 56 years. They were mostly female (72%), had diabetes 2 (95.6%) and all types of neuropathic pain. The medication had improved the sensory disorders as well as the intensity of pain in diabetic neuropathy patients. There was also a significant increase in sensory conduction velocity in the right median nerve and left sciatic nerves during the electromyographic tests. No clinical or biological side effects have been noted. The combination of CMP and UTP is useful in the treatment of diabetic neuropathy. We recommended its use for diabetic patients with neuropathy.
Key words: Neuropathy, diabetes, CMP, UTP, Senegal.